World Federation of Societies of Biological Psychiatry (WFSBP) guidelines for biological treatment of schizophrenia, part 2: Long-term treatment of schizophrenia

Peter Falkai, Thomas Wobrock*, Jeffrey Lieberman, Birte Glenthoj, Wagner F. Gattaz, Hans Jürgen Möller, A. Carlo Altamura, Nancy Andreasen, Thomas R E Barnes, Helmut Beckmann, Jorge Ciprian-Ollivier, Tim Crow, Anthony David, Michael Davidson, Bill Deakin, Helio Elkis, Lars Farde, Wolfgang Gaebel, Bernd Gallhofer, Jes GerlachSteven Richard Hirsch, Carlos R. Hojaij, Assen Jablensky, John Kane, Takuja Kojima, Lars von Knorring, Patrick McGorry, Herbert Meltzer, Driss Moussaoui, Franz Müller-Spahn, Jean Pierre Olie, A. Pacheco Palha, Mitsumoto Sato, Heinrich Sauer, Nina Schooler, Daniel Weinberger, Shigeto Yamawaki

*Corresponding author for this work

Research output: Contribution to journalReview article

115 Citations (Scopus)

Abstract

These guidelines for the biological treatment of schizophrenia were developed by an international Task Force of the World Federation of Societies of Biological Psychiatry (WFSBP). The goal during the development of these guidelines was to review systematically all available evidence pertaining to the treatment of schizophrenia, and to reach a consensus on a series of practice recommendations that are clinically and scientifically meaningful based on the available evidence. These guidelines are intended for use by all physicians seeing and treating people with schizophrenia. The data used for developing these guidelines have been extracted primarily from various national treatment guidelines and panels for schizophrenia, as well as from meta-analyses, reviews and randomised clinical trials on the efficacy of pharmacological and other biological treatment interventions identified by a search of the MEDLINE database and Cochrane Library. The identified literature was evaluated with respect to the strength of evidence for its efficacy and then categorised into four levels of evidence (A-D). This second part of the guidelines covers the long-term treatment as well as the management of relevant side effects. These guidelines are primarily concerned with the biological treatment (including antipsychotic medication, other pharmacological treatment options, electroconvulsive therapy, adjunctive and novel therapeutic strategies) of adults suffering from schizophrenia.

Original languageEnglish (US)
Pages (from-to)5-40
Number of pages36
JournalWorld Journal of Biological Psychiatry
Volume7
Issue number1
DOIs
StatePublished - Mar 1 2006

Fingerprint

Biological Psychiatry
Schizophrenia
Guidelines
Therapeutics
Pharmacology
Electroconvulsive Therapy
Advisory Committees
MEDLINE
Antipsychotic Agents
Libraries
Meta-Analysis
Consensus
Randomized Controlled Trials
Databases
Physicians

Keywords

  • Anti-psychotics
  • Biological treatment
  • Evidence-based medicine
  • Long-term treatment
  • Practice guidelines
  • Schizophrenia

ASJC Scopus subject areas

  • Psychiatry and Mental health
  • Biological Psychiatry

Cite this

Falkai, Peter ; Wobrock, Thomas ; Lieberman, Jeffrey ; Glenthoj, Birte ; Gattaz, Wagner F. ; Möller, Hans Jürgen ; Altamura, A. Carlo ; Andreasen, Nancy ; Barnes, Thomas R E ; Beckmann, Helmut ; Ciprian-Ollivier, Jorge ; Crow, Tim ; David, Anthony ; Davidson, Michael ; Deakin, Bill ; Elkis, Helio ; Farde, Lars ; Gaebel, Wolfgang ; Gallhofer, Bernd ; Gerlach, Jes ; Hirsch, Steven Richard ; Hojaij, Carlos R. ; Jablensky, Assen ; Kane, John ; Kojima, Takuja ; von Knorring, Lars ; McGorry, Patrick ; Meltzer, Herbert ; Moussaoui, Driss ; Müller-Spahn, Franz ; Olie, Jean Pierre ; Pacheco Palha, A. ; Sato, Mitsumoto ; Sauer, Heinrich ; Schooler, Nina ; Weinberger, Daniel ; Yamawaki, Shigeto. / World Federation of Societies of Biological Psychiatry (WFSBP) guidelines for biological treatment of schizophrenia, part 2 : Long-term treatment of schizophrenia. In: World Journal of Biological Psychiatry. 2006 ; Vol. 7, No. 1. pp. 5-40.
@article{062c161f26c747d886e3a6da2d2d5834,
title = "World Federation of Societies of Biological Psychiatry (WFSBP) guidelines for biological treatment of schizophrenia, part 2: Long-term treatment of schizophrenia",
abstract = "These guidelines for the biological treatment of schizophrenia were developed by an international Task Force of the World Federation of Societies of Biological Psychiatry (WFSBP). The goal during the development of these guidelines was to review systematically all available evidence pertaining to the treatment of schizophrenia, and to reach a consensus on a series of practice recommendations that are clinically and scientifically meaningful based on the available evidence. These guidelines are intended for use by all physicians seeing and treating people with schizophrenia. The data used for developing these guidelines have been extracted primarily from various national treatment guidelines and panels for schizophrenia, as well as from meta-analyses, reviews and randomised clinical trials on the efficacy of pharmacological and other biological treatment interventions identified by a search of the MEDLINE database and Cochrane Library. The identified literature was evaluated with respect to the strength of evidence for its efficacy and then categorised into four levels of evidence (A-D). This second part of the guidelines covers the long-term treatment as well as the management of relevant side effects. These guidelines are primarily concerned with the biological treatment (including antipsychotic medication, other pharmacological treatment options, electroconvulsive therapy, adjunctive and novel therapeutic strategies) of adults suffering from schizophrenia.",
keywords = "Anti-psychotics, Biological treatment, Evidence-based medicine, Long-term treatment, Practice guidelines, Schizophrenia",
author = "Peter Falkai and Thomas Wobrock and Jeffrey Lieberman and Birte Glenthoj and Gattaz, {Wagner F.} and M{\"o}ller, {Hans J{\"u}rgen} and Altamura, {A. Carlo} and Nancy Andreasen and Barnes, {Thomas R E} and Helmut Beckmann and Jorge Ciprian-Ollivier and Tim Crow and Anthony David and Michael Davidson and Bill Deakin and Helio Elkis and Lars Farde and Wolfgang Gaebel and Bernd Gallhofer and Jes Gerlach and Hirsch, {Steven Richard} and Hojaij, {Carlos R.} and Assen Jablensky and John Kane and Takuja Kojima and {von Knorring}, Lars and Patrick McGorry and Herbert Meltzer and Driss Moussaoui and Franz M{\"u}ller-Spahn and Olie, {Jean Pierre} and {Pacheco Palha}, A. and Mitsumoto Sato and Heinrich Sauer and Nina Schooler and Daniel Weinberger and Shigeto Yamawaki",
year = "2006",
month = "3",
day = "1",
doi = "10.1080/15622970500483177",
language = "English (US)",
volume = "7",
pages = "5--40",
journal = "World Journal of Biological Psychiatry",
issn = "1562-2975",
publisher = "Informa Healthcare",
number = "1",

}

Falkai, P, Wobrock, T, Lieberman, J, Glenthoj, B, Gattaz, WF, Möller, HJ, Altamura, AC, Andreasen, N, Barnes, TRE, Beckmann, H, Ciprian-Ollivier, J, Crow, T, David, A, Davidson, M, Deakin, B, Elkis, H, Farde, L, Gaebel, W, Gallhofer, B, Gerlach, J, Hirsch, SR, Hojaij, CR, Jablensky, A, Kane, J, Kojima, T, von Knorring, L, McGorry, P, Meltzer, H, Moussaoui, D, Müller-Spahn, F, Olie, JP, Pacheco Palha, A, Sato, M, Sauer, H, Schooler, N, Weinberger, D & Yamawaki, S 2006, 'World Federation of Societies of Biological Psychiatry (WFSBP) guidelines for biological treatment of schizophrenia, part 2: Long-term treatment of schizophrenia', World Journal of Biological Psychiatry, vol. 7, no. 1, pp. 5-40. https://doi.org/10.1080/15622970500483177

World Federation of Societies of Biological Psychiatry (WFSBP) guidelines for biological treatment of schizophrenia, part 2 : Long-term treatment of schizophrenia. / Falkai, Peter; Wobrock, Thomas; Lieberman, Jeffrey; Glenthoj, Birte; Gattaz, Wagner F.; Möller, Hans Jürgen; Altamura, A. Carlo; Andreasen, Nancy; Barnes, Thomas R E; Beckmann, Helmut; Ciprian-Ollivier, Jorge; Crow, Tim; David, Anthony; Davidson, Michael; Deakin, Bill; Elkis, Helio; Farde, Lars; Gaebel, Wolfgang; Gallhofer, Bernd; Gerlach, Jes; Hirsch, Steven Richard; Hojaij, Carlos R.; Jablensky, Assen; Kane, John; Kojima, Takuja; von Knorring, Lars; McGorry, Patrick; Meltzer, Herbert; Moussaoui, Driss; Müller-Spahn, Franz; Olie, Jean Pierre; Pacheco Palha, A.; Sato, Mitsumoto; Sauer, Heinrich; Schooler, Nina; Weinberger, Daniel; Yamawaki, Shigeto.

In: World Journal of Biological Psychiatry, Vol. 7, No. 1, 01.03.2006, p. 5-40.

Research output: Contribution to journalReview article

TY - JOUR

T1 - World Federation of Societies of Biological Psychiatry (WFSBP) guidelines for biological treatment of schizophrenia, part 2

T2 - Long-term treatment of schizophrenia

AU - Falkai, Peter

AU - Wobrock, Thomas

AU - Lieberman, Jeffrey

AU - Glenthoj, Birte

AU - Gattaz, Wagner F.

AU - Möller, Hans Jürgen

AU - Altamura, A. Carlo

AU - Andreasen, Nancy

AU - Barnes, Thomas R E

AU - Beckmann, Helmut

AU - Ciprian-Ollivier, Jorge

AU - Crow, Tim

AU - David, Anthony

AU - Davidson, Michael

AU - Deakin, Bill

AU - Elkis, Helio

AU - Farde, Lars

AU - Gaebel, Wolfgang

AU - Gallhofer, Bernd

AU - Gerlach, Jes

AU - Hirsch, Steven Richard

AU - Hojaij, Carlos R.

AU - Jablensky, Assen

AU - Kane, John

AU - Kojima, Takuja

AU - von Knorring, Lars

AU - McGorry, Patrick

AU - Meltzer, Herbert

AU - Moussaoui, Driss

AU - Müller-Spahn, Franz

AU - Olie, Jean Pierre

AU - Pacheco Palha, A.

AU - Sato, Mitsumoto

AU - Sauer, Heinrich

AU - Schooler, Nina

AU - Weinberger, Daniel

AU - Yamawaki, Shigeto

PY - 2006/3/1

Y1 - 2006/3/1

N2 - These guidelines for the biological treatment of schizophrenia were developed by an international Task Force of the World Federation of Societies of Biological Psychiatry (WFSBP). The goal during the development of these guidelines was to review systematically all available evidence pertaining to the treatment of schizophrenia, and to reach a consensus on a series of practice recommendations that are clinically and scientifically meaningful based on the available evidence. These guidelines are intended for use by all physicians seeing and treating people with schizophrenia. The data used for developing these guidelines have been extracted primarily from various national treatment guidelines and panels for schizophrenia, as well as from meta-analyses, reviews and randomised clinical trials on the efficacy of pharmacological and other biological treatment interventions identified by a search of the MEDLINE database and Cochrane Library. The identified literature was evaluated with respect to the strength of evidence for its efficacy and then categorised into four levels of evidence (A-D). This second part of the guidelines covers the long-term treatment as well as the management of relevant side effects. These guidelines are primarily concerned with the biological treatment (including antipsychotic medication, other pharmacological treatment options, electroconvulsive therapy, adjunctive and novel therapeutic strategies) of adults suffering from schizophrenia.

AB - These guidelines for the biological treatment of schizophrenia were developed by an international Task Force of the World Federation of Societies of Biological Psychiatry (WFSBP). The goal during the development of these guidelines was to review systematically all available evidence pertaining to the treatment of schizophrenia, and to reach a consensus on a series of practice recommendations that are clinically and scientifically meaningful based on the available evidence. These guidelines are intended for use by all physicians seeing and treating people with schizophrenia. The data used for developing these guidelines have been extracted primarily from various national treatment guidelines and panels for schizophrenia, as well as from meta-analyses, reviews and randomised clinical trials on the efficacy of pharmacological and other biological treatment interventions identified by a search of the MEDLINE database and Cochrane Library. The identified literature was evaluated with respect to the strength of evidence for its efficacy and then categorised into four levels of evidence (A-D). This second part of the guidelines covers the long-term treatment as well as the management of relevant side effects. These guidelines are primarily concerned with the biological treatment (including antipsychotic medication, other pharmacological treatment options, electroconvulsive therapy, adjunctive and novel therapeutic strategies) of adults suffering from schizophrenia.

KW - Anti-psychotics

KW - Biological treatment

KW - Evidence-based medicine

KW - Long-term treatment

KW - Practice guidelines

KW - Schizophrenia

UR - http://www.scopus.com/inward/record.url?scp=33744993897&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=33744993897&partnerID=8YFLogxK

U2 - 10.1080/15622970500483177

DO - 10.1080/15622970500483177

M3 - Review article

C2 - 16509050

AN - SCOPUS:33744993897

VL - 7

SP - 5

EP - 40

JO - World Journal of Biological Psychiatry

JF - World Journal of Biological Psychiatry

SN - 1562-2975

IS - 1

ER -